Skip to main content
StemCell Longevita
Flagship condition guide · Medical review required

Stem Cell Therapy for erectile dysfunction in Turkey – Istanbul

Written by
StemCell Longevita Editorial Team
Medically reviewed by
Professor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
Last reviewed
Next scheduled review

How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards

Evidence-aware guide to stem cell and exosome therapy for erectile dysfunction in Turkey: cause assessment, candidacy, alternatives and Istanbul planning.

Can stem cell therapy help erectile dysfunction?

Mesenchymal stem cell and exosome therapies are not approved treatments for erectile dysfunction. Small early-phase studies have been reported, but they have not demonstrated a consistent, clinically meaningful improvement over standard care or placebo. Established therapies — cause-directed workup, PDE5 inhibitors, vacuum devices, intracavernosal therapy and, in selected patients, penile implants — have strong evidence and remain the mainstay.

Key facts

Approval status
Not approved for erectile dysfunction
Evidence
Small studies; no consistent efficacy signal versus placebo
Standard care
Cause-directed workup, PDE5 inhibitors, ICI, devices, implants

What we know

  • PDE5 inhibitors have strong evidence in most vasculogenic and neurogenic ED.

What remains uncertain

  • Whether intracavernosal MSC or exosome injection provides benefit beyond established therapies.

Medically reviewed questions

There is no reliable evidence of a curative effect from MSC or exosome injection.

No — established therapies have evidence and remain first-line.

Often yes — ED can be an early cardiovascular signal and warrants specialist assessment.

This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.

Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy

Evidence at a glance — Erectile dysfunction

A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.

Human studies available?
Yes — early-stage only
Randomised trials?
A small number of randomised and placebo-controlled pilot trials
Main outcomes studied
  • IIEF-5 score
  • Penile Doppler parameters
  • Safety
Long-term evidence
Very limited
Regulatory approval for this indication
  • United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
  • European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
  • United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
  • Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
Role at our centre
Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it

What kind of evidence exists

  • Mechanism (laboratory): Documented
  • Animal / preclinical: Documented
  • Early human (phase 1/2, uncontrolled): Documented
  • Controlled human (randomised or sham-controlled): Documented
  • Regulatory approval: Not established

Sources

Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.

Evidence last reviewed: Next scheduled review: Medical reviewer: Prof. Dr. Erdal KaraözRead our editorial and evidence policy

This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.

Medically reviewed by Prof. Dr. Erdal Karaöz
Share:

Records before recommendations

A proposed route is discussed only after diagnosis, investigations, current care and travel fitness have been reviewed.

No outcome guarantee

The evidence, uncertainty and reasons not to proceed are explained. Established care remains part of the decision.

Plan for continuity

Istanbul logistics, discharge documents and follow-up should connect with the clinician managing care at home.

What this page is for

A decision guide for patients comparing care

This page is for patients and families researching regenerative options for erectile dysfunction and comparing an Istanbul medical review with care available at home. It explains the evidence limits, questions that determine candidacy, reasons not to travel, protocol decisions, realistic expectations, costs and return-home follow-up.

Clinical decision guide

Before considering stem cell therapy for erectile dysfunction

The key question: Has the underlying vascular, neurological, hormonal, medication-related or psychological cause been assessed before considering an investigational procedure?

Evidence status

Stem cell and exosome approaches for erectile dysfunction remain investigational. Improvement in erections or vascular function cannot be guaranteed.

Standard care first

Cardiovascular risk assessment, medication review, PDE5 inhibitors, counselling, devices, injections and urology options should be considered first.

What the review checks

Onset, cardiovascular risk, diabetes, hormones, medication, prostate or pelvic treatment, neurological history and prior ED therapies.

When we redirect

Unstable cardiovascular disease, unexplained symptoms, active infection, untreated endocrine disease or inability to pause unsafe medication requires redirection.

Planning treatment in Istanbul

Confirm privacy, exact intervention and delivery route, medication instructions, recovery limits and follow-up with the home urologist.

Continue your research

ED evidence guideFertility and sexual health pillarScientific evidencePost-procedure guidance

How are stem cell and exosome approaches discussed for erectile dysfunction?

Stem cell and exosome research in erectile dysfunction explores vascular and tissue-signalling hypotheses. It has not established reliable recovery of erectile function, and the biological rationale may not match hormonal, neurological, medication-related or psychological causes.

A responsible review identifies the likely cause first and considers cardiovascular risk, standard urology options and the exact delivery route before discussing an investigational procedure.

Who may be considered?

Candidacy is never decided from age or diagnosis alone. A medical review looks for a clear clinical question, stable health, appropriate prior care and goals that can be followed after return home.

  • The likely vascular, neurological, hormonal, medication or psychological cause has been assessed
  • Cardiovascular fitness and standard urology options have been reviewed
  • Realistic goals and a plan for confidential follow-up

Who may not be suitable?

Unstable cardiovascular disease, unexplained symptoms, active infection, untreated endocrine disease or inability to pause unsafe medication requires redirection.

Active infection, unstable medical disease, pregnancy, active cancer treatment or inability to complete safe follow-up also require postponement, redirection or further specialist review.

How is a protocol for erectile dysfunction planned?

Route, dose, session count and stay length cannot be responsibly prescribed from a webpage. The written plan follows record review and should explain why each element is being proposed.

  1. 1

    Records and diagnosis review

    Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether erectile dysfunction is stable enough for elective travel.

  2. 2

    Product and route discussion

    If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient.

  3. 3

    Individual written plan

    Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined.

  4. 4

    Discharge and follow-up handover

    Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.

What results can realistically be expected?

The purpose of follow-up is to measure safety and agreed clinical goals—not to retrofit ordinary variation into a success claim.

  • There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication.
  • Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration.
  • The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome.
  • No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.

Why patients consider StemCell Longevita for erectile dysfunction

Patients may choose StemCell Longevita when they want an Istanbul review pathway built around records, written decisions and return-home coordination rather than a promise of results. These are the service standards to confirm during consultation:

Records are reviewed before a treatment recommendation or travel booking is requested

The medical team can explain why an enquiry may be declined or redirected

The proposed product, source, testing, route and traceability documents are identified in writing

Investigational options are distinguished from established treatment and medication is not stopped without the home clinician

The quotation separates clinical services, travel support, exclusions and potential extra costs

Discharge documents and a follow-up pathway are prepared for continuity with the home specialist

International patient journey for erectile dysfunction

Confirm privacy, exact intervention and delivery route, medication instructions, recovery limits and follow-up with the home urologist.

  1. 1

    Private record review

    Send recent reports, imaging or test results and a current medication list. The team may request more information or advise against travel.

  2. 2

    Written planning before booking

    Confirm the proposed intervention, evidence status, exclusions, estimated stay, companion or accessibility needs, package inclusions and total quoted cost.

  3. 3

    Assessment in Istanbul

    Clinical review on arrival confirms that health status and records still support the plan. Treatment should be paused if new risks are identified.

  4. 4

    Discharge and return home

    Travel timing and support are adapted to erectile dysfunction. Warning signs, medication continuity and relevant documents are reviewed before departure.

  5. 5

    Remote follow-up

    Scheduled check-ins document safety and agreed outcomes, while the home specialist remains responsible for established disease management and urgent care.

How much does treatment for erectile dysfunction cost in Turkey?

A responsible quotation follows medical review. It should show the proposed clinical service and travel support separately enough for you to compare it with options in the UK, US, Germany or another home country.

  • Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ.
  • Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included.
  • Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.

Frequently asked questions about erectile dysfunction

Stem cell and exosome approaches for erectile dysfunction remain investigational. Improvement in erections or vascular function cannot be guaranteed.

Cardiovascular risk assessment, medication review, PDE5 inhibitors, counselling, devices, injections and urology options should be considered first.

Onset, cardiovascular risk, diabetes, hormones, medication, prostate or pelvic treatment, neurological history and prior ED therapies. Unstable cardiovascular disease, unexplained symptoms, active infection, untreated endocrine disease or inability to pause unsafe medication requires redirection.

Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether erectile dysfunction is stable enough for elective travel. If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient. Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined. Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.

There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication. Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration. The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome. No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.

Stay length is confirmed only after records, the proposed route, monitoring needs, mobility and companion requirements are reviewed. Patients should not book travel from a generic online timeline.

Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ. Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included. Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.

Records can be reviewed, but advanced disease does not automatically mean treatment is appropriate. Unstable cardiovascular disease, unexplained symptoms, active infection, untreated endocrine disease or inability to pause unsafe medication requires redirection. The review may recommend local specialist care or supportive planning instead of travel.

Start with a medical-record review

Send recent reports, investigations, medication lists and the questions you are discussing with your home specialist. Review may lead to a request for more information, a discussion of options, or advice not to travel.

Related clinical questions

Where this page sits in the wider picture.

Start here

Compare with

What the evidence says

Cost and next step

Related pages